Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

摘要: Background: Researches on immunotherapy of glioma has been increasing exponentially in recent years. However, autoimmune-like side effects current immune checkpoint blockade hindered the clinical application glioma. The discovery TIM-3, a tumor-specific checkpoint, shed new light solution this dilemma. We aimed at investigating role TIM-3 transcriptome level and its relationship with practice Methods: A cohort 325 patients RNA-seq data from Chinese Glioma Genome Atlas (CGGA project) was analyzed, results were well validated TCGA 699 gliomas. R language used as main tool for statistical analysis graphical work. Results: enriched glioblastoma (the most malignant glioma) IDH-wildtype can act potential marker mesenchymal molecular subtype according to transcriptional classification scheme closely related functions glioma, especially T cell mediated response tumor cytotoxicity directed against target. Moreover, PD-L1 played almost exactly same inflammatory activation Clinically, high expression an independent indicator poor prognosis. Conclusion: is pathology Meanwhile, plays specific response. Therefore, promising target immunotherapeutic strategies, providing alternative treatment when gains resistance antibodies PD-1/PD-L1.